AIM Vaccine Co (HKSE:06660) LT-Debt-to-Total-Asset: 0.05 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06660 AIM Vaccine Co Ltd HKSE:06660
61 GF Score
Price HK$1.70
GF Value HK$4.08
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is AIM Vaccine Co LT-Debt-to-Total-Asset?

AIM Vaccine Co HKSE:06660 -0.29% 61 LT-Debt-to-Total-Asset is 0.05 as of Jun. 2026. GuruFocus rates HKSE:06660 with a GF Score™ of 61/100 and a GF Value™ of HK$4.08 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AIM Vaccine Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.05.

AIM Vaccine Co's long-term debt to total assets ratio declined from Jun. 2025 (0.06) to Jun. 2026 (0.05). It may suggest that AIM Vaccine Co is progressively becoming less dependent on debt to grow their business.

AIM Vaccine Co  (HKSE:06660) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AIM Vaccine Co LT-Debt-to-Total-Asset Related Terms

AIM Vaccine Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for AIM Vaccine Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM Vaccine Co LT-Debt-to-Total-Asset Chart

AIM Vaccine Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.03 0.04 0.08 0.06 0.06

AIM Vaccine Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.06 0.06 0.05
HKSE:06660
61GF Score
AIM Vaccine Co Ltd HKSE:06660
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM Vaccine Co LT-Debt-to-Total-Asset Calculation

AIM Vaccine Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=394.273/7229.844
=0.05

AIM Vaccine Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=361.951/7327.728
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.05 mean?
AIM Vaccine Co (HKSE:06660) has a LT-Debt-to-Total-Asset of 0.05 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AIM Vaccine Co and its competitors.
Is AIM Vaccine Co's LT-Debt-to-Total-Asset too high?
AIM Vaccine Co's current LT-Debt-to-Total-Asset is 0.05. Overall, AIM Vaccine Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM Vaccine Co's LT-Debt-to-Total-Asset compare to VRTX and REGN?
AIM Vaccine Co's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on AIM Vaccine Co and its competitors. AIM Vaccine Co's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM Vaccine Co stock overvalued right now?
Based on GuruFocus' analysis, AIM Vaccine Co (HKSE:06660) is currently considered Possible Value Trap. The stock's GF Value™ is HK$4.08, compared to a current price of HK$1.70 — trading 58.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. AIM Vaccine Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For AIM Vaccine Co (HKSE:06660), the current LT-Debt-to-Total-Asset is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM Vaccine Co (HKSE:06660) Overvalued in 2026?

Based on GuruFocus' analysis, AIM Vaccine Co stock appears to be undervalued. The current stock price of HK$1.70 is trading 58.5% below its estimated GF Value™ of HK$4.08. GuruFocus considers AIM Vaccine Co to be Possible Value Trap.

Key valuation signals for HKSE:06660:

  • LT-Debt-to-Total-Asset: 0.05
  • GF Value™: HK$4.08 vs. price of HK$1.70 (58.5% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the HKSE:06660 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM Vaccine Co Business Description

Address 2 Ronghua South Road, 26th Floor, Building T6, Han’s Plaza, Economic Technological Development Area, Beijing, CHN
AIM Vaccine Co Ltd is a China-based full-chain vaccine company engaged in the research and development, manufacturing, and commercialization of vaccine products. The company's commercialized products include recombinant HBV vaccines, freeze-dried human rabies vaccines, inactivated HAV vaccines, Group A, C, Y, and W135 meningococcal polysaccharide vaccines, bivalent inactivated HFRS vaccines, and mumps vaccines. The company generates the majority of its revenue from the PRC.
61GF Score

Get the complete analysis for HKSE:06660

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.70
Price
HK$4.08
GF Value